Related sites
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

لائحة الأدوية الأساسية 2018


Foreword
 
Essential medicines as defined by the World Health Organization (WHO) are “those that satisfy the priority health care needs of the population. They are selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness. Essential medicines are intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality and adequate information, and at a price the individual and the community can afford. The implementation of the concept of essential medicines is intended to be flexible and adaptable to many different situations; exactly which medicines are regarded as essential remains a national responsibility”.
 
The WHO Model list of Essential Medicines revised every two years provides a template and serves as a guide for countries to prepare their own lists taking into consideration local priorities.

Based on the current version of the WHO Model List of Essential medicines 20th edition published in 2017, the Ministry of Public Health in Lebanon through the Quality Assurance of Pharmaceutical Products Program prepared the National List of Essential Medicines EML 2018, four years after the last edition in 2014. The EML 2018 contains around 350 medicinal products and was prepared over one year by a Committee of Experts.

The EML is aligned with the National Drug Formulary and National Health Programs such as EIP Mother & Child, TB Control, HIV/AIDS, Malaria, National Mental Health Program and Primary Healthcare. The formulation and strengths of medicines listed in the EML are those mentioned under these National Health Programs and National Drug Formulary.
 
The Lebanese EML 2018 contains a core list and complementary list:

The core list presents a list of minimum medicine needs for a basic health care system, listing the most efficacious, safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment.

The complementary list presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost-effectiveness in a variety of settings.
 
The list is divided into 30 sections related to the main Therapeutic classes of medicines and arranged in three columns;
 
  1. INN of the medicine,
  2. Dosage form and strength of the medicine
  3. Official Status of the medicine 
 
Medicines and dosage forms are listed in alphabetical order within each section with no implication of preference for one form over another.
 
The following symbols are used in the list to indicate the status of the medicine:
 
R: Registered drug in the Ministry of Public Health
NR: Non Registered drug in the Ministry of Public Health
HIV: included in the HIV Program
M: included in the MALARIA Program
NMHP: included in the NATIONAL MENTAL HEALTH Program
TB: included in the TUBERCULOSIS Program
U: provided through UNICEF Program
Y: provided through YMCA Program
[a]: indicates that there is an age or weight restriction on use of the medicine.
 
An index listing the Medicines by alphabetical order is available at the end of the document facilitating retrieval of information and easy reference.
 
We hope that all health providers would embrace this document as important tool for management of medicines and rationalizing prescription in the country. The EML 2018 welcomes comments from healthcare professionals; such comments help us to ensure that the National Essential medicines list remains relevant to practice.
 
The list can be accessed from the official website of the Ministry of Public Health:  www.moph.gov.lb
 

List of Essential Medicines Lebanon 2018
    1
    ...
ATC Name B/G Ingredients Dosage Form Price ↓
J05AB14 VALGANCICLOVIR ARROW G Valganciclovir (HCl) - 450mg 450mg Tablet, coated L.L
L01CD01 PANATAXEL G Paclitaxel - 100mg/16.7ml 100mg/16.7ml Injectable concentrated solution L.L
L04AA04 THYMOGLOBULINE 5mg/ml BioTech Rabbit anti-human thymocyte immunoglobulin - 25mg/5ml 25mg/5ml Injectable powder for solution L.L
L01FX13 PADCEV 30mg Injectable powder for concentrate for solution L.L
L01FX06 QARZIBA 4.5 mg/ml Injectable lyophilised powder for solution L.L
L01XA01 CIPINTU G Cisplatin - 50mg/50ml 50mg/50ml Injectable concentrated solution L.L
L01BC02 5-FROTU G Fluorouracil - 1000mg/20ml 1000mg/20ml Injectable solution L.L
V03AE02 SEVELAMER CARBONATE ARROW G Sevelamer carbonate - 800mg 800mg Tablet, film coated L.L
B02BD02 XYNTHA BioTech Moroctocog alfa - 500IU 500IU Injectable lyophilised powder for solution+diluent L.L
L01AX03 TEMOZOLOMIDE ACCORD G Temozolomide - 20mg 20mg Capsule, hard L.L
H05BX01 CINACALCET ARROW BioTech Cinacalcet - 60mg 60mg Tablet, coated, scored L.L
H05BX01 CINACALCET ARROW BioTech Cinacalcet - 30mg 30mg Tablet, coated L.L
L03AA02 NEUTROMAX BioTech Filgrastim - 300mcg/ml 300mcg/ml Injectable solution L.L
S01BA01 OZURDEX B Dexamethasone - 700mcg 700mcg Implant L.L
L01FX24 TECVAYLI BioTech Teclistamab - 10mg/ml 10mg/ml Injectable solution L.L
L01FD04 ENHERTU BioTech Trastuzumab deruxtecan - 100mg 100mg Injectable powder for concentrate for solution L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 400mg/20ml 400mg/20ml Injectable concentrated solution L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 200mg/10ml 200mg/10ml Injectable concentrated solution L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 162mg/0.9ml 162mg/0.9ml Injectable solution L.L
L04AC07 ACTEMRA BioTech Tocilizumab - 80mg/4ml 80mg/4ml Injectable concentrated solution L.L
L04AA06 IMUNOCELL G Mycophenolate mofetil - 500mg 500mg Tablet, film coated L.L
M05BA08 ZOLEDRO-DENK G Zoledronic acid - 4mg/5ml 4mg/5ml Injectable concentrate for solution L.L
L04AA23 TYSABRI BioTech Natalizumab - 300mg/15ml 300mg/15ml Injectable concentrated solution L.L
L01FC01 DARZALEX BioTech Daratumumab - 400mg/20ml 400mg/20ml Injectable concentrate for solution L.L
D11AH05 DUPIXENT BioTech Dupilumab - 300mg 300mg Injectable solution L.L
L01AX03 TEGOZOL G Temozolomide - 100mg 100mg Capsule L.L
V03AF03 EUROFOLIC G Folic acid as Calcium Folinate Hydrate - 100mg/10ml 10mg/ml Injectable solution L.L
L01BC05 GEMCITABINE THYMOORGAN G Gemcitabine (HCl) - 200mg 200mg Injectable powder for solution L.L
L01XA02 KARBOTEEN G Carboplatin - 150mg/15ml 150mg/15ml Injectable solution L.L
L04AC05 STELARA BioTech Ustekinumab - 45mg 45mg Injectable solution L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026